$10.04
0.30% yesterday
NYSE, Jun 13, 10:00 pm CET
ISIN
US68622V1061
Symbol
OGN

Organon & Co. Stock price

$10.04
+1.60 18.96% 1M
-5.26 34.38% 6M
-4.88 32.71% YTD
-10.47 51.05% 1Y
-23.21 69.80% 5Y
-23.21 69.80% 10Y
-23.21 69.80% 20Y
NYSE, Closing price Fri, Jun 13 2025
-0.03 0.30%
ISIN
US68622V1061
Symbol
OGN
Sector
Industry

Key metrics

Market capitalization $2.62b
Enterprise Value $11.03b
P/E (TTM) P/E ratio 3.48
EV/FCF (TTM) EV/FCF 18.82
EV/Sales (TTM) EV/Sales 1.75
P/S ratio (TTM) P/S ratio 0.42
P/B ratio (TTM) P/B ratio 4.79
Dividend yield 11.12%
Last dividend (FY24) $1.12
Revenue growth (TTM) Revenue growth -0.84%
Revenue (TTM) Revenue $6.29b
EBIT (operating result TTM) EBIT $1.38b
Free Cash Flow (TTM) Free Cash Flow $586.00m
Cash position $547.00m
EPS (TTM) EPS $2.89
P/E forward 2.96
P/S forward 0.42
EV/Sales forward 1.77
Short interest 8.97%
Show more

Is Organon & Co. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Organon & Co. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Organon & Co. forecast:

2x Buy
25%
3x Hold
38%
3x Sell
38%

Analyst Opinions

8 Analysts have issued a Organon & Co. forecast:

Buy
25%
Hold
38%
Sell
38%

Financial data from Organon & Co.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
6,294 6,294
1% 1%
100%
- Direct Costs 2,695 2,695
4% 4%
43%
3,599 3,599
4% 4%
57%
- Selling and Administrative Expenses 1,749 1,749
7% 7%
28%
- Research and Development Expense 453 453
11% 11%
7%
1,674 1,674
6% 6%
27%
- Depreciation and Amortization 296 296
21% 21%
5%
EBIT (Operating Income) EBIT 1,378 1,378
3% 3%
22%
Net Profit 750 750
28% 28%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Organon & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organon & Co. Stock News

Neutral
GlobeNewsWire
about 9 hours ago
LOS ANGELES, June 13, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 22, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) securities between October 31, 2024 to April 30, 2025, inclusive (the “Class Period”).
Neutral
PRNewsWire
about 12 hours ago
LOS ANGELES , June 13, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of the federal securities laws. Shareholders who purchased the Company's securities between October 31, 2024 and April 30, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 22, 2...
Neutral
GlobeNewsWire
one day ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Organon To Contact Him Directly To Discuss Their Options
More Organon & Co. News

Company Profile

Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020 and is headquartered in Jersey City, NJ.

Head office United States
CEO Kevin Ali
Employees 10,000
Founded 2020
Website www.organon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today